Does Rallies show live market data for TXG?

Rallies combines live market context with ticker research for TXG, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.

TXG (10x Genomics, Inc. Class A Common Stock) Stock Analysis

10x Genomics, Inc. Class A Common Stock (TXG) is a publicly traded Healthcare sector company. As of May 21, 2026, TXG trades at $23.86 with a market cap of $2.72B and a P/E ratio of -137.82. TXG moved +7.58% today. Year to date, TXG is +30.90%; over the trailing twelve months it is +164.10%. Its 52-week range spans $6.78 to $26.45. Analyst consensus is buy with an average price target of $24.10. Rallies surfaces TXG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the latest TXG stock research?

10x Genomics, Inc. Class A Common Stock (TXG) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. TXG moved +7.58% today. Analyst consensus is buy.

TXG Key Metrics

Key financial metrics for TXG
Metric	Value
Price	$23.86
Market Cap	$2.72B
P/E Ratio	-137.82
EPS	$-0.17
Dividend Yield	0.00%
52-Week High	$26.45
52-Week Low	$6.78
Volume	2.61M
Avg Volume	0
Revenue (TTM)	$638.78M
Net Income	$-22.66M
Gross Margin	69.60%

Latest TXG News

10x Genomics Sees Q1 Revenue of $150.8M, Launches Atera Platform — May 7, 2026
10x Genomics Debuts Atera Platform for Whole-Transcriptome Spatial Analysis — Apr 19, 2026
PerturbAI and 10x Genomics Unveil 8 Million-Cell In Vivo CRISPR Atlas — Mar 17, 2026
10x Genomics Q4 Beats Estimates, Narrows Loss to $0.13; Shares Jump 10.5% — Feb 13, 2026
10x Genomics to Analyze 1,000 Autoimmune Cases, Establish CLIA Lab and Launch 20,000-Sample AI Oncology Project — Jan 12, 2026

Recent TXG Insider Trades

Saxonov Serge sold 5.00K (~$122.78K) on Apr 14, 2026.
Saxonov Serge sold 5.00K (~$97.61K) on Mar 24, 2026.
Saxonov Serge sold 10.00K (~$191.30K) on Mar 23, 2026.

TXG Analyst Consensus

12 analysts cover TXG: 0 strong buy, 4 buy, 8 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $24.10.

Common questions about TXG

What can I research for TXG on Rallies?: 10x Genomics, Inc. Class A Common Stock (TXG) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. TXG moved +7.58% today. Analyst consensus is buy.
Does Rallies show live market data for TXG?: Rallies combines live market context with ticker research for TXG, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.